Navigation Links
Fulgent Therapeutics Announces That CAP (College of American Pathologists) Has Accredited Their Clinical Laboratory
Date:10/24/2013

Temple City, CA (PRWEB) October 24, 2013

Fulgent Therapeutics, a CLIA Certified Laboratory, is proud to announce accreditation by the College of American Pathologists (CAP). CAP’s Laboratory Accreditation Program is recognized by the United States government as being equal-to or more-stringent-than the government’s own inspection program. With this accreditation, Fulgent's Diagnostic Lab is a part of an internationally recognized group of facilities that meet the highest standards of excellence and best practices in laboratory operations.    

The CAP accreditation process was comprised of CAP inspectors that examined Fulgent’s laboratory procedure, quality control, safety program, staff qualifications, equipment, facilities, and overall management and laboratory records.

Fulgent Therapeutics has recently announced a wide range of diagnostic panels for a variety of inherited diseases, including cardiology, pediatrics, and neurology as well as inherited cancer predisposition.

Additional information: info(at)fulgent-therapeutics(dot)com or 626-350-0537 x106.

About Fulgent Therapeutics LLC: Fulgent’s diagnostic lab was CLIA approved in May 2012. Fulgent Diagnostics provides affordable next generation genetic tests using massively parallel processes to a global community. Tests range from hereditary cancers to esoteric diseases. For a complete list of tests available please visit: fulgent-therapeutics.com/testing.    

About the College of American Pathologists:

The College of American Pathologists (CAP) is a medical society that serves more than 18,000 physician members and the global laboratory community. It is the world’s largest association composed exclusively of board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care. More information about the CAP can be found at http://www.cap.org.

Fulgent Therapeutics LLC
4978 Santa Anita Ave, Ste. 205
Temple City, CA
91780

Read the full story at http://www.prweb.com/releases/2013/10/prweb11264218.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Fulgent Therapeutics Announces Their Comprehensive Hereditary Cancer Test Including BRCA1 and BRCA2 Analysis
2. Multiple Myeloma Therapeutics Future Discussed in In-demand MP Advisors Report Published at MarketPublishers.com
3. American Assoc. for Cancer Research co-hosts conference on molecular targets and cancer therapeutics
4. Global Dermatophytic Onychomycosis Therapeutics Market 2012 - 2016: Worldwide Industry Latest Market Share, Growth, Size, Trends, Strategy And Forecast Research Report
5. Global Huntington’s Disease Therapeutics Industry
6. Obesity Therapeutics to 2019 - Safety Concerns Hinder Drug Performance Despite Large Market Opportunity
7. Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
8. Multiple Sclerosis Therapeutics Market to 2019 – Treatment Diversification and Pipeline Innovation to Drive Growth, Says a New Report at RnRMarketResearch.com
9. Refractory Hematological Malignancies (MDS, AML) Market Emerging Therapeutics Analysis Available at ReportsnReports.com
10. Pain Management Therapeutics Market Will Decline USD 29.47 Billion in 2018 : Transparency Market Research
11. Pain Management Therapeutics Market Will Decline USD 29.47 Billion in 2018 : Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... On Saturday, ... a treadmill relay – Miles by Moonlight to raise money for the American Heart ... or more. , Teams will work together to keep their treadmills moving for ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... wound care advancements to physician colleagues, skilled nursing facility medical directors and other ... Treacherous Waters of Wound Care." , "At many of these conferences we get ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
Breaking Medicine Technology: